Oxford Biomedica PLC Deferred Bonus Plan (5685M)
May 08 2015 - 1:00AM
UK Regulatory
TIDMOXB
RNS Number : 5685M
Oxford Biomedica PLC
08 May 2015
Deferred Bonus Plan Awards
London, UK - 8 May 2015: Oxford BioMedica plc ("Oxford
BioMedica" or "the Group" or "OXB") (LSE:OXB), a leading gene and
cell therapy Group, today announces the grant of awards to its
executive directors under the Oxford BioMedica 2015 Deferred Bonus
Plan ( "DBP") on 7 May 2015.
Under the terms of the DBP, approved by shareholders at the
Annual General Meeting on 7 May 2015, the executive directors have
been granted awards to cover 50% of their bonus awards for 2014, as
disclosed in the 2014 Annual Report. The number of shares subject
to each award has been determined by the average closing price of
the Company's shares for the five business days up to and including
6 May 2015.
Director Title Number Total shares Percentage
of shares over which of issued
subject options shares
to DBP are held under option
award (notes
1,2)
------------- ------------------- ----------- ------------- --------------
Chief Executive
John Dawson Officer 1,370,154 21,683,927 0.84%
------------- ------------------- ----------- ------------- --------------
Chief Development
Paul Blake Officer 228,359 2,109,375 0.08%
------------- ------------------- ----------- ------------- --------------
Peter Chief Business
Nolan Officer 762,159 11,079,037 0.43%
------------- ------------------- ----------- ------------- --------------
Chief Financial
Tim Watts Officer 871,916 14,727,233 0.57%
------------- ------------------- ----------- ------------- --------------
Notes:
1. Includes the 2015 grants described
2. Includes 2014 DBP awards to be met by market purchased shares
held by the Oxford BioMedica Employee Benefit Trust
Each award has been granted in the form of a nil-cost option and
will become exercisable as to one third of the shares subject to it
on each of the first three anniversaries of the grant date.
This notification is made pursuant to Disclosure and
Transparency Rule 3.1.4.
- Ends -
For further information, please
contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive Officer 783 000
Tim Watts, Chief Financial Officer
Consilium Strategic Communications Tel: +44 (0)20
Mary-Jane Elliott/Matthew Neal/Chris 3709 5700
Welsh/Laura Thornton
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell
therapy Group with an unrivalled portfolio of gene therapy products
in development and a platform of exclusive and pioneering
technologies with which it designs, develops and manufactures
unique gene-based medicines for some of world's largest
pharmaceutical companies. Leveraging its proprietary LentiVector(R)
IP and gene delivery system technology platform and unique tumour
antigen (5T4), Oxford BioMedica is advancing its pipeline of seven
gene therapy products addressing diseases for which there are
currently no treatments or that are inadequately treated today,
including ocular and central nervous system disorders. OXB
Solutions, the Group's industry-leading manufacturing and
development business, provides services to collaborators and
partners working in gene and cell therapy, including Novartis and
Immune Design Corp. In addition, the Group has licenced products
and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich,
Biogen Idec, Emergent BioSolutions and ImaginAb. Further
information is available at www.oxfordbiomedica.co.uk and
www.oxbsolutions.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSEANSXEDSSEFF
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024